Clinical Research Directory

Inclusion Criteria: * Patients must be between 18\<X\< 65 years of age. * The participant must be willing and able to give written informed consent. The volunteer must provide his/her consent on his or her behalf, a legally acceptable representative (i.e., an International Harmonization Council \[ICH\] and adopted by local law as appropriate can be used) must give informed consent on his/her behalf. * PCR test COVID-19 positive diagnosis and mild to moderate disease stage is required. * The participant must agree not to receive vaccines administered for COVID-19 during the study. Exclusion Criteria: * Patients \< 18 years of age, * Positive diagnosis of severe COVID-19 with symptoms of basic severity: patients with respiratory distress, signs of mental confusion and impaired consciousness that develop depending on the severity of the stage of the disease, * Patients on active antiviral therapy, * Patients with creatine clearance \< 30 ml/min and renal impairment, * NYHA III-IV, Stage D heart failure patients requiring frequent hospitalization, * Uncontrolled coagulopathy, * Patients with advanced liver failure, * Patients with active infections such as hepatitis B, hepatitis C and HIV, diseases requiring systemic treatment, * Patients with active malignancy and known history of cancer, * Those who do not have sufficient psychic state to disrupt working rounds, * Active drug users, * Known hypersensitivity and allergic reaction to the components of the preparation, * Current participation in another interventional treatment study with an investigational agent, * Recent use of the investigational product within 28 days of the first dose of the investigational product use or presence of a research device during screening, * Pregnant or breastfeeding women, * Patients who did not give written informed consent.